## Contents

1. The Impact of Preclinical Planning and Study Outcome on the Risk Management of Biologics
   By Dan Wierda, PhD, ATS

2. Risk Management Regulations in the US
   By Brande Yaist, Debra Gash, Debasish Dey, MD, PhD, MPH and Nayan Acharya

3. Regulations Related to Risk Management in Japan
   By Yong Huang, MD, PhD and Hiroshi Nakane

4. European Experience With Additional Risk Minimization and Its Impact on Benefit-Risk
   By Stephen Heaton, Gabriela Wirsching, Suzanne Frankfort, Ursula Maria Schmidt-Ott and Yuhong Wang

5. Risk Management of Medicines and Biologics in Australia
   By Judy Bingham, MHSc

6. Benefit-Risk Management: Current Trends and Future Directions
   By Meredith Smith, PhD, MPA

7. Risk Management in the Medical Device and Food Industries
   By Salma Michor, PhD, MBA, CMgr, CQA, RAC

8. Quality Risk Management (QRM)—A Gateway to Quality by Design (QbD)
   By Peter Schiemann, PhD and Beat Widler, PhD

9. Benefit-Risk Assessment: Art or Science?
   By Mariette Boerstoel-Streefland, MD, MSc, MBA

    By Elaine B. Taylor and Kiley DePolo

11. Use of Pregnancy Registries for Risk Management
    By Jessica Albano, Vikki Brown, MD, Angie Graves, Nadja Merkusheva and Roxana Silica

12. Clinical Evaluation Reports
    By Evangeline Loh, PhD and Chris Brodrick

13. Risk Communication: Learning From Experts, Learning From Evidence
    By Lee L. Zwaniger, PhD

14. Postmarketing Pharmacoepidemiology Database Study Development to Evaluate Long-Term Drug Safety—An Example, Prolia...
    By Fei Xue

15. Risk Management in the Future: Looking Into the Crystal Ball
    By Tjeerd van Staa, MD, MSc

    By Elaine H. Morrato, DrPH, MPH, CPH

17. EHR Use for Stimulated Reporting of Adverse Drug Events
    By Angela Walker, MD and Richard Loomis, MD

Index

About the Editors